Circulating cell-free DNA (cfDNA) samples from 79 patients with B-cell lymphomas...significant difference in ORR was observed in patients with NPM1_NR4A3 and SEPT6_TRIM33 fusions...Histologically, 55 (69.6%) patients were diagnosed with DLBCL...Majorities of the patients received R-CHOP (34.2%) or R-COEP (27.8%) as their first-line therapy. Fifty-seven percentage of patients achieved CR (N=26) or PR (N=19) to treatments they received, while 8.9% of patient had a stable (SD, N=2) or progressive disease (PD, N=5), during a median follow-up of 7.08 months.